Baxter International investors are clamoring for a payoff from Robert Parkinson's years-long R&D spending spree.
Investors hope Baxter's R&D blitz will offset anemic plasma-business growth
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.